Immediate Impact
10 standout
Citing Papers
Enhancement of EPR Effect for Passive Tumor Targeting: Current Status and Future Perspectives
2025 Standout
An Update on the Nitrogen Heterocycle Compositions and Properties of U.S. FDA-Approved Pharmaceuticals (2013–2023)
2024 Standout
Works of H. S. Williamson being referenced
Design Strategy for the EPR Tumor-Targeting of 1,2-Bis(sulfonyl)-1-alkylhydrazines
2021
1,2‐Bis(methylsulfonyl)‐1‐(2‐chloroethyl)‐2‐[[1‐(4‐nitrophenyl)ethoxy]carbonyl]hydrazine (KS119): a Cytotoxic Prodrug with Two Stable Conformations Differing in Biological and Physical Properties
2011
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| H. S. Williamson | 159 | 75 | 9 | 59 | 13 | 227 | |
| Benny Poedjono | 85 | 27 | 33 | 25 | 115 | ||
| Ian G. Donaldson | 50 | 63 | 89 | 19 | 287 | ||
| Jingjing Zong | 66 | 24 | 1 | 106 | 24 | 243 | |
| Michael J. Tompkins | 109 | 21 | 195 | 16 | 248 | ||
| Jacob R. Sheehan | 133 | 14 | 187 | 12 | 263 | ||
| Shengjie Sun | 76 | 90 | 27 | 118 | 18 | 290 | |
| Yong Liu | 95 | 82 | 8 | 21 | 278 | ||
| B. Corre | 170 | 109 | 25 | 22 | 249 | ||
| Zhiling Long | 62 | 30 | 86 | 16 | 181 | ||
| Yu Jiang | 34 | 33 | 137 | 21 | 288 |
All Works
Loading papers...